Contact
searchSearch
HMP Global
Login

B-Cell Lymphoma Videos

Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
Stephen Edge, MD.
Videos
Clinical Pathways in Practice at Roswell Park Cancer Center
09/05/2023
Stephen Edge, MD
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president...
09/05/2023
Journal of Clinical Pathways
Manali Kamdar Headshot
Videos
Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma
07/19/2023
Manali Kamdar, MD
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of...
07/19/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
The Benefits of Incorporating Radiation Therapy Into the Treatment of Primary CNS Lymphoma
01/05/2023
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting,...
01/05/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
Retrospective Analysis of Survival Outcomes Following Treatment for Primary CNS Lymphoma
01/05/2023
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS,...
01/05/2023
Journal of Clinical Pathways
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
Alice J Chen, PhD
Videos
The Value of Reducing CAR-T Treatment Wait Times Among Patients With Diffuse Large B-cell Lymphoma
10/04/2022
Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.
Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.
Alice J Chen, PhD, found that...
10/04/2022
Journal of Clinical Pathways
Patrick Bliven, MD
Videos
Patterns of Therapy Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
08/03/2022
Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...
Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...
Patrick Bliven, MD, discusses...
08/03/2022
Journal of Clinical Pathways
Peter Riedell, MD
Videos
Real-World Safety, Efficacy, and Utilization of Axicabtagene Ciloleucel and Tisagenlecleucel for B-Cell Lymphomas
01/21/2022
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses...
01/21/2022
Journal of Clinical Pathways
Patrick Connor Johnson, MD
Videos
Physician Survey Reveals Key Attributes for Third-Line Treatment Selection for DLBCL
10/18/2021
Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.
Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.
Patrick Connor Johnson, MD,...
10/18/2021
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use